

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Jean-Paul Cassart et al.

Serial No.: 10/650,608

Art Unit: 1642

Filing Date: August 28, 2003

Examiner: Min-Tam Davis

For: Tumour Specific animal Proteins

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

☒ Copies of the references are enclosed (7, 10, 11, 12, and 14).

☒ Copies of the references were submitted in parent application Serial No. 10/226,872.
(37 CFR 1.98(d))

☐ A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

☐ **The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).**

B. ☒ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
(1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311,
whichever occurs first.

☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

☒ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. **[or]**
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and

- ☒ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

☐ Please charge any required fees to Deposit Account No.07-1392.

Respectfully Submitted,

/Eric J. Kron/
Eric J. Kron
Attorney of Record
Registration No. 45,941

Date: 15 Feb 2007
Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8961
Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				SERIAL NO.		10/650,608	
				FILING DATE		August 28, 2003	
				APPLICANT		Cassart et al.	
				GROUP		1642	
				EXAMINER		Min-Tam Davis	
				ATTORNEY DOCKET NO.		BC45300-1US	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1.	20050260634	11/24/2005	Baldwin et al.			
	2.	6,451,320	9/2002	Stephenne et al.			
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	3.	BOWIE et al., Science 257 :1306-1310 (1990).					
	4.	BURGESS et al., J. of Cell Biology 11 :2129-2138 (1990).					
	5.	FOWLKES et al., T-Cell Tolerance, Current Opinino in Immunology 5 :873-879 (1993).					
	6.	GILLIES et al.m, Human Antibodies and Hybromomas, 1(1) :47-54 (1990).					
	7.	HOOS et al., A Clinical Development Paradigm for Cancer Vaccines and Related Biologics, J. Immunotherapy 30(1) :1-15 (Jan. 2007).					
	8.	KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cells, An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163 :231-245 (1986).					
	9.	LAZAR et al., Molecular and Cell Biology 8 :1247-1252 (1988).					
	10.	MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene <i>MAGE-3</i> and Presented by HLA-A1, Int. J. Cancer 80 :219-230 (1999).					
	11.	OKA et al., Induction of <i>WT1</i> (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38) :13885-13890 (Sept. 2004).					
	12.	ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9) :909-915 (Sept. 2004).					
	13.	TAO et al., The J. of Immunology 143(8) :2595-2601 (1989).					
	14.	TSURUMA et al., Peptide-based vaccination for colorectal cancer, Expert Opin. Biol. Ther. 5(6) :799-807 (2005).					
	15.	Protein GenPep Accession Number: NP 005161.1					
	16.	Protein GenPep Accession Number: AAB86993.1					
		ZHANG et al., Induction of Specific T Cell Tolerance by Fas Ligand-Expressing Antigen-Presenting Cells, J. of Immunology 162 :1423-1430 (1999).					
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							